OBJECTIVE: To assess trends in use of long-acting opioids during delivery hospitalizations. METHODS: The Perspective database, an administrative inpatient database that includes medication receipt, was analyzed to evaluate patterns of long-acting opioid use during delivery hospitalizations from January 2006 through March 2015. Medications evaluated included methadone, formulations including buprenorphine and extended-release formulations of oxycodone, morphine, fentanyl, and other opioids. Temporal trends in use of these medications were determined. Unadjusted and adjusted models evaluating the role of demographic and hospital factors were created evaluating both use of these medications and risk for severe morbidity. Risk for severe morbidity was determined based on Centers for Disease Control and Prevention criteria. RESULTS: Our analysis included 2,994,630 delivery hospitalizations meeting study criteria. Over the entire study period, use of long-acting opioids increased significantly from 457 to 844 per 100,000 deliveries. Although buprenorphine and methadone use increased, use of other long-acting opioids decreased. In 2006, methadone and buprenorphine accounted for less than one third of all long-acting opioids used during delivery hospitalizations. By 2015, buprenorphine and methadone represented 73.5% of long-acting opioids used. In adjusted and unadjusted models, risk for severe morbidity was significantly lower with buprenorphine or methadone compared with other long-acting opioids. Restricting the cohort to only women with drug abuse or dependence, risk for severe morbidity was lower with methadone and buprenorphine than without any long-acting opioids. CONCLUSION: Increased use of methadone and buprenorphine in this study supports the feasibility of use of these medications during pregnancy and uptake of clinical recommendations for women with opioid use disorder. Use of methadone and buprenorphine is associated with decreased maternal morbidity, although causation cannot be presumed from this study model.
OBJECTIVE: To assess trends in use of long-acting opioids during delivery hospitalizations. METHODS: The Perspective database, an administrative inpatient database that includes medication receipt, was analyzed to evaluate patterns of long-acting opioid use during delivery hospitalizations from January 2006 through March 2015. Medications evaluated included methadone, formulations including buprenorphine and extended-release formulations of oxycodone, morphine, fentanyl, and other opioids. Temporal trends in use of these medications were determined. Unadjusted and adjusted models evaluating the role of demographic and hospital factors were created evaluating both use of these medications and risk for severe morbidity. Risk for severe morbidity was determined based on Centers for Disease Control and Prevention criteria. RESULTS: Our analysis included 2,994,630 delivery hospitalizations meeting study criteria. Over the entire study period, use of long-acting opioids increased significantly from 457 to 844 per 100,000 deliveries. Although buprenorphine and methadone use increased, use of other long-acting opioids decreased. In 2006, methadone and buprenorphine accounted for less than one third of all long-acting opioids used during delivery hospitalizations. By 2015, buprenorphine and methadone represented 73.5% of long-acting opioids used. In adjusted and unadjusted models, risk for severe morbidity was significantly lower with buprenorphine or methadone compared with other long-acting opioids. Restricting the cohort to only women with drug abuse or dependence, risk for severe morbidity was lower with methadone and buprenorphine than without any long-acting opioids. CONCLUSION: Increased use of methadone and buprenorphine in this study supports the feasibility of use of these medications during pregnancy and uptake of clinical recommendations for women with opioid use disorder. Use of methadone and buprenorphine is associated with decreased maternal morbidity, although causation cannot be presumed from this study model.
Authors: Elena V Kuklina; Maura K Whiteman; Susan D Hillis; Denise J Jamieson; Susan F Meikle; Samuel F Posner; Polly A Marchbanks Journal: Matern Child Health J Date: 2007-08-10
Authors: Alexander Kulik; Jeremy A Rassen; Jessica Myers; Sebastian Schneeweiss; Joshua Gagne; Jennifer M Polinski; Jun Liu; Michael A Fischer; Niteesh K Choudhry Journal: Circ Cardiovasc Interv Date: 2012-06-26 Impact factor: 6.546
Authors: Matthew Miller; Catherine W Barber; Sarah Leatherman; Jennifer Fonda; John A Hermos; Kelly Cho; David R Gagnon Journal: JAMA Intern Med Date: 2015-04 Impact factor: 21.873
Authors: Jonah J Stulberg; Conor P Delaney; Duncan V Neuhauser; David C Aron; Pingfu Fu; Siran M Koroukian Journal: JAMA Date: 2010-06-23 Impact factor: 56.272
Authors: Hendrée E Jones; Karol Kaltenbach; Sarah H Heil; Susan M Stine; Mara G Coyle; Amelia M Arria; Kevin E O'Grady; Peter Selby; Peter R Martin; Gabriele Fischer Journal: N Engl J Med Date: 2010-12-09 Impact factor: 91.245
Authors: Jason D Wright; Sharyn N Lewin; Monjri Shah; William M Burke; Shing M Lee; Xuming Sun; Thomas J Herzog Journal: Ann Surg Date: 2011-06 Impact factor: 12.969
Authors: Barbara K Zedler; Ashley L Mann; Mimi M Kim; Halle R Amick; Andrew R Joyce; E Lenn Murrelle; Hendrée E Jones Journal: Addiction Date: 2016-06-30 Impact factor: 6.526
Authors: Gregory G Grecco; David L Haggerty; Kaitlin C Reeves; Yong Gao; Danielle Maulucci; Brady K Atwood Journal: Addict Biol Date: 2022-03 Impact factor: 4.280
Authors: Gregory G Grecco; Braulio Muñoz; Gonzalo Viana Di Prisco; Emma H Doud; Brandon M Fritz; Danielle Maulucci; Yong Gao; Amber L Mosley; Anthony J Baucum; Brady K Atwood Journal: eNeuro Date: 2022-04-20
Authors: Gregory G Grecco; Briana E Mork; Jui-Yen Huang; Corinne E Metzger; David L Haggerty; Kaitlin C Reeves; Yong Gao; Hunter Hoffman; Simon N Katner; Andrea R Masters; Cameron W Morris; Erin A Newell; Eric A Engleman; Anthony J Baucum; Jiuen Kim; Bryan K Yamamoto; Matthew R Allen; Yu-Chien Wu; Hui-Chen Lu; Patrick L Sheets; Brady K Atwood Journal: Elife Date: 2021-03-16 Impact factor: 8.140